Blood Biomarkers Predict Neuroendocrine Tumor Response to Radiopharmaceutical Therapy
A simple blood draw can help determine if peptide receptor radionuclide therapy is effective in a patient with neuroendocrine cancer.
Read More
Search Results for: lung cancer
Stilla Tech and Atila BioSystems Co-Develop Digital PCR Kits for Oncology
Stilla Technologies and Atila BioSystems agreed to market digital PCR kits and assays produced by Atila for use on Stilla’s naica system.
Read More
SEngine Precision Medicine Gets New York CLEP Approval for Tumor Test
SEngine has been certified through the NY State Department of Health’s CLEP program to perform the PARIS Test on samples from the state.
Read More
How a Community Health Center Sped Up Cancer Diagnostics
A co-location model for cancer diagnostic services reported a reduction in the time it took to diagnose cancer at a community health center.
Read More
FDA Approves VENTANA PD-L1 as a CDx for NSCLC Subtype
The FDA approved the VENTANA PD-L1 (SP263) Assay as a CDx to identify NSCLC patients eligible for treatment with Libtayo (cemiplimab).
Read More